{"filing":{"accession_number":"0001193125-26-386630","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"d152057d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526386630/d152057d6k.htm"},"events":[{"id":32431,"run_id":29795,"accession_number":"0001193125-26-386630","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The 6-K discloses Week 52 data from the reACHin Trial sentinel cohort showing that TransCon CNP (navepegritide) achieved stabilization or improvement in foramen magnum stenosis and linear growth benefits in infants with achondroplasia. This is a material clinical trial milestone for a pivotal Phase 2 program, but it is not a discrete earnings release, M\u0026A activity, executive change, or other specifically-named event type. The disclosure represents a significant operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory prospects.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":35599,"accession_number":"0001193125-26-386630","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The 6-K discloses Week 52 data from the reACHin Trial sentinel cohort showing that TransCon CNP (navepegritide) achieved stabilization or improvement in foramen magnum stenosis and linear growth benefits in infants with achondroplasia. This is a material clinical trial milestone for a pivotal Phase 2 program, but it is not a discrete earnings release, M\u0026A activity, executive change, or other specifically-named event type. The disclosure represents a significant operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T21:21:37.802703+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-09"}]}